Dermata Therapeutics, Inc. filed a Form 8-K on November 17, 2026, disclosing a press release highlighting additional results and photos from a recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the company's once-weekly skin renewal treatment.

Key Highlights

  • Study results released: The company issued a press release on November 17, 2026, with additional results and photos from its recently completed cosmetic clinical study.
  • Product evaluated: The study evaluated Tome Foundational Treatment, described by the company as its recently launched once-weekly skin renewal treatment.
  • Order milestone: According to the filing, the company has received over 1,000 orders since launch.
  • Exchange listing: The company's common stock, par value $0.0001 per share, trades on NASDAQ:DRMA under the Nasdaq Capital Market.
  • Emerging growth company: The registrant indicated that it qualifies as an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

Dermata Therapeutics Discloses Cosmetic Clinical Study Findings for Tome Treatment

Dermata Therapeutics, Inc. (NASDAQ:DRMA) filed a current report on November 17, 2026, under Item 8.01 (Other Events), disclosing that the company issued a press release on the same date. The press release, according to the filing, highlighted "additional results and photos from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company's recently launched once-weekly skin renewal treatment."

The filing further disclosed that the company has received over 1,000 orders since the launch of Tome Foundational Treatment. No detailed clinical data, efficacy metrics, or financial figures related to the product or its sales were included in the body of the 8-K itself. The underlying press release was referenced but not reproduced in the filing text provided.

The report was signed by Gerald T. Proehl, Chief Executive Officer, on behalf of Dermata Therapeutics, Inc., a Delaware-incorporated company headquartered at 3525 Del Mar Heights Rd., #322, San Diego, CA 92130. The company carries Commission File Number 001-40739 and IRS Employer Identification No. 86-3218736.

What Was Disclosed

Dermata Therapeutics filed an 8-K on November 17, 2026, disclosing a press release covering additional results and photos from a cosmetic clinical study of its Tome Foundational Treatment, and noting the product has received over 1,000 orders since launch.